Also categorized in Business of Medicine:
Targeting the Type I Interferon Pathway to Treat Patients With Lupus
x hide permanently

Research Agreement with Lilly to Identify COVID-19 Antibodies Announced

Medical News

news-medical.net

Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies. These collaborative studies aim to build on Lilly's current portfolio of neutralizing antibodies by exploring novel cocktails, half-life extension technologies, and strategies to further enhance potency. Neutralizing antibodies have the potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease, such as the elderly and those with compromised immune systems.

The research team will evaluate antibody candidates, delivered from Lilly through their partnership ...